Vertex Pharmaceuticals VRTX has observed the following analyst ratings within the last quarter:

In the last 3 months, 10 analysts have offered 12-month price targets for Vertex Pharmaceuticals. The company has an average price target of $232.5 with a high of $331.00 and a low of $170.00.

Below is a summary of how these 10 analysts rated Vertex Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This current average has decreased by 6.08% from the previous average price target of $247.56.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.